GPhA Comments on JAMA Internal Medicine National Survey of Physicians

Published Online: Tuesday, January 8, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Study Concludes Public Bares ‘Unnecessary Expense’ When Generics Are Not Used

WASHINGTON, D.C. (JANUARY 8, 2013) – The Generic Pharmaceutical Association (GPhA) today issued the following statement regarding a national survey of the prescribing behaviors of physicians and published January 7, 2013, in JAMA Internal Medicine (formerly Archives of Internal Medicine).

“The JAMA Internal Medicine study demonstrates that we are still leaving savings on the table that could be achieved by increasing the use of generic drugs. The use of safe and effective generic versions of brand name drugs currently saves consumers and the U.S. healthcare system $1 billion every other day, a total of $192 billion in 2011. But, as significant as these savings are, there still is room for improvement and we must realize that generics are part of the solution to sustaining affordable healthcare in America,” said GPhA President and CEO Ralph G. Neas.

The survey concluded that prescribing brand-name drugs when generic drugs are available “generates unnecessary medical expenditures, the costs of which are borne by the public in the form of higher copayments, increased health insurance costs, and higher Medicare and Medicaid expenses.” Prescribing a brand-name drug when a generic is available “is a huge source of wasteful spending that can be prevented,” says Eric Campbell, Ph.D., professor of medicine at Harvard Medical School and team leader of the study.

Results of the survey revealed that about four in 10 doctors “sometimes or often” prescribe a brand-name drug when a less costly generic version of the drug is available just because their patients requested the brand drug. The study also found that brand industry gifting (such as free food or beverage) and drugs samples “increase the likelihood that physicians will prescribe a brand name.”

“Nearly 80 percent of the 4 billion prescriptions written in the U.S. last year were filled using safe and effective generic versions of their brand name counterpart drugs,” Neas said. “This means that millions of consumers, including many seniors on fixed incomes, were able to purchase the medicines they need to live longer, healthier lives without having to give up other necessities,” he added.

“As the new Congress continues its work on the debt and deficit, we urge that Members reject any legislative proposal that could lessen the timely availability of affordable generics. This includes saying ‘no’ to any proposal that would restrict the right of drug manufacturers to settle patent litigation out of court, which has proven to be the one sure way of bringing generics to market prior to brand drug patent expiration,” Neas said. He added that initiatives to promote generic use in Medicare and Medicaid and to reduce the market exclusivity period for biologics from 12 years to seven, would generate significant additional savings for taxpayers and the government.

  • Read the JAMA Internal Medicine study here
  • Additional information on the savings generated by patent settlements here
  • 2012 Generic Savings Study here
Related Articles
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
The approximately 4% of American adults with bipolar disorder face a litany of challenges, from unpredictable recurrences of hypomanic/manic or depressive episode to poor impulse control.
The Generic Pharmaceutical Association announced today that Ralph G. Neas, President and CEO, would be stepping down from his position in the fall of 2015.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$